AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05094037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Removable cam walker boot
Description: Standard of care device given to diabetic foot ulcer patients.
Study NCT05094037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Additional education, counseling and encouragement of use of the orthosis beyond the current standard of care.
Study NCT05196932 — intervention group
Intervention type: DEVICE
Intervention: Novel point-of-care, semi-quantitative test for SARS-CoV-2 antibodies
Description: A drop of blood obtained by both finger-prick and venipuncture will be placed on the test card, which has been activated by the addition of diluent. Visual clumping of red blood cells (RBCs) will be seen within minutes if SARS-CoV-2 antibodies are present. Additionally, the COVID card is semi-quantitative, meaning that the yielded hemagglutination pattern will correlate with the concentration of antibodies in the serum.~A research team member will be present at bedside to provide their interpretation based on an established visual agglutination scoring system.
Study NCT04894578 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: reverse distal metatarsal minimal-invasive osteotomy
Description: minimal-invasive oblique osteotomy of the two or three metatarsal bones using a straight burr
Study NCT04894578 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tarsometatarsal fusion
Description: open procedure with fusion and screw and plate fixation of two to three tarsometatarsal joints
Study NCT06449235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Description: Chemical name: MK-3102 Class: Dipeptidyl peptidase-4 (DPP-4) inhibitor~Mechanism of Action:~Inhibits DPP-4 enzyme, thereby increasing incretin levels. Enhances glucose-dependent insulin secretion. Suppresses glucagon secretion. Improves β-cell function of the pancreas. Reduces hepatic glucose output. Administration: Once-weekly oral dosing.
Study NCT06449235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphonylureas
Description: Chemical Name: Sulphonylureas Class: Sulphonylureas~Mechanism of Action:~Stimulates insulin release from pancreatic beta cells. Enhances the sensitivity of beta cells to glucose. Reduces hepatic glucose production. Increases peripheral glucose uptake and utilization. Administration: Typically administered once or twice daily, depending on the specific medication and patient needs.
Study NCT05922280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: subtalar and talo-crural mobilization
Description: Traction, Antero Posterior (AP) and Postero Anterior (PA) Maitland Grade III oscillatory mobilizations of 2Hz with 120 oscilations per minute, 3 sets for 5 minutes with 1 min of rest between sets at subtalar and talocrural joint would be performed. The mobilization would be large amplitude rhythmic oscillations from the joint mid into end-range muscle spasm/stiffness (translation taken to tissue resistance). Duration will be 20 minutes with 2 sessions per week, total 12 sessions would be performed on each patient in the total period of 6 weeks.~Patients will be guided to follow self foot care examination given by IWGDF Guidelines.
Study NCT05922280 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: International Working Group of the Diabetic Foot care guidelines
Description: Patients will continue their usual activities according to International Working Group on Diabetic Foot (IWGDF) guidelines including the measures of inspecting the feet, self- examination for callus, pre-ulcerative signs or deformity. They will be restrict barefoot walking in-door and outdoors. To wash their feet daily with careful drying, to use emollients to prevent dryness and cut their nails straight across. Monitor the foot skin temperature for inflammation, wear orthotic insoles for preventing abundant callus.~Patients will perform active ROM exercises 5 times per week for duration of 30 minutes for 6 weeks:Ankle pumps, Supination and Pronation, Drawing score from 0 to 9, Leg Flexion and Extension
Study NCT06449235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Chemical Name: Metformin Class: Biguanide~Mechanism of Action:~Decreases hepatic glucose production. Improves insulin sensitivity in peripheral tissues. Enhances peripheral glucose uptake and utilization. Reduces intestinal absorption of glucose. Administration: Administered orally, usually once or twice daily with meals.
Study NCT06449235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Other DPP4-i
Description: Chemical Names: Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Alogliptin Class: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors~Mechanism of Action:~Inhibits DPP-4 enzyme, thereby increasing incretin levels. Enhances glucose-dependent insulin secretion. Suppresses glucagon secretion. Improves β-cell function of the pancreas. Reduces hepatic glucose output. Administration: Typically administered orally once daily. Dosage may vary depending on the specific medication and patient needs.
Study NCT06449235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiazolidinediones
Description: Chemical Name: Thiazolidinediones (e.g., Pioglitazone, Rosiglitazone) Class: Thiazolidinediones (TZDs)~Mechanism of Action:~Activates peroxisome proliferator-activated receptor-gamma (PPAR-γ) in adipose tissue, muscle, and liver.~Increases insulin sensitivity in peripheral tissues. Enhances glucose uptake and utilization in muscle and adipose tissue. Reduces hepatic glucose production. Administration: Administered orally, typically once daily. Dosage may vary based on the specific medication and patient response.
Study NCT06449235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-Glucosidase Inhibitor
Description: Chemical Name: Alpha-Glucosidase Inhibitors (e.g., Acarbose, Miglitol) Class: Alpha-Glucosidase Inhibitors~Mechanism of Action:~Inhibits alpha-glucosidase enzymes in the small intestine. Delays the breakdown and absorption of complex carbohydrates. Reduces postprandial blood glucose levels. Administration: Administered orally, typically taken with the first bite of each main meal. Dosage may vary based on the specific medication and patient response.
Study NCT06449235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon-Like Peptide-1
Description: Chemical Name: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists (e.g., Exenatide, Liraglutide, Dulaglutide, Semaglutide) Class: GLP-1 Receptor Agonists~Mechanism of Action:~Mimics the action of endogenous GLP-1. Enhances glucose-dependent insulin secretion. Suppresses glucagon secretion. Slows gastric emptying. Promotes satiety and reduces food intake. Improves β-cell function of the pancreas. Administration: Administered via subcutaneous injection, with frequency varying from twice daily to once weekly, depending on the specific medication.
Study NCT06449235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Receptor Agonists (GLP1RA)
Description: Chemical Name: GLP-1 Receptor Agonists (GLP1RA) (e.g., Exenatide, Liraglutide, Dulaglutide, Semaglutide) Class: Glucagon-Like Peptide-1 Receptor Agonists~Mechanism of Action:~Activates GLP-1 receptors. Enhances glucose-dependent insulin secretion. Suppresses glucagon secretion. Slows gastric emptying. Promotes satiety and reduces food intake. Improves β-cell function of the pancreas. Administration: Administered via subcutaneous injection, with frequency varying from twice daily to once weekly, depending on the specific medication.
Study NCT06449235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2 inhibitors
Description: Chemical Name: Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors (e.g., Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin) Class: SGLT2 Inhibitors~Mechanism of Action:~Inhibits SGLT2 in the proximal renal tubules. Reduces reabsorption of filtered glucose from the renal tubules. Increases urinary glucose excretion. Lowers blood glucose levels independently of insulin. Administration: Administered orally, typically once daily. Dosage may vary based on the specific medication and patient response.
Study NCT06455761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-NI-FAPI04
Description: Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-DOTA-NI-FAPI04. Tracer doses of 68Ga-DOTA-NI-FAPI04 will be used to detect tumors by PET/CT.
Study NCT06455761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI/18F-FDG
Description: Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI or 3.7 MBq (0.1 mCi)/Kg 18F-FDG. Tracer doses of 68Ga-FAPI/18F-FDG will be used to detect tumors by PET/CT.
Study NCT04857190 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Parker Flex-it Directional Stylet
Description: Parker Flex-it Directional Stylet
Study NCT04857190 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Malleable Stylet
Description: Conventional Malleable Stylet
Study NCT06530524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: Injection of onabotulinumtoxinA into the at-risk major salivary glands
Study NCT06530524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of normal saline into the at-risk major salivary glands
Study NCT05030935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mHealth App
Description: In short, mHA contains three main functions for the user: a) a reminder for switching the patient position, b) training for preventive care habits and c) the possibility for patient evaluation in order to determine the need for the use of support surfaces.
Study NCT04890522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triprilimab(JS001)
Description: Maximum 6 cycles for combined therapy and maintenance for up to 2 years.
Study NCT04890522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triprilimab(JS001)
Description: Maximum 6 cycles for combined therapy and maintenance for up to 2 years.
Study NCT04890522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Maximum 6 cycles for combined therapy.
Study NCT04890522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Maximum 6 cycles for combined therapy.
Study NCT04890522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Maximum 6 cycles for combined therapy.
Study NCT04890522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Maximum 6 cycles for combined therapy.
Study NCT04532151 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Non-invasive skin imaging assessment
Description: Intervention Description : (Limit: 1000 characters) Do not repeat information already included in arm/group descriptions. Specify details not covered in associated Arm~One session of Non-invasive skin imaging assessment contained:~* an examination on LC-OCT~* an examination on LC-OCT-doppler~* a fluid silicone molding~* an examination on HD ultrasound~The measurements will be applied on 3 skin sites: the dorsal surface of the finger, the inner face and the outer surface of the forearm.~The imaging assessment lasts 30 minutes in a dimly lit room where the humidity and temperature are stable.
Study NCT06292533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Description: Ultrapulse is a is a laser beauty device using erbium-doped yttrium aluminium garnet laser (er:YAG). Er:YAG laser is a laser with wavelength of 2940nm which is able to penetrate into the dermis to a depth of 3-4 mm, and energy absorption occurs in the area of the dermal papilla, resulting in an increase in blood circulation of the papilla and activation of metabolism in the hair follicle.
Study NCT04384679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrophilic polymer and potassium ferrate powder
Description: Application with pressure until hemostasis is achieved
Study NCT06480071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline, 0.05% Nasal Spray
Description: 2 sprays each nostril before the excercise test.
Study NCT06162026 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: RACS app
Description: risk assessment questions, symbol matching task, voice tasks
Study NCT04604730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary anastomosis without protective stoma
Description: Primary anastomosis without protective stoma
Study NCT04604730 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anastomosis with protective stoma
Description: Anastomosis with protective stoma
Study NCT05699460 — intervention group
Intervention type: OTHER
Intervention: This is an observational study.
Description: This is an observational study.
Study NCT04877782 — intervention group
Intervention type: DEVICE
Intervention: Transcutaneous vagus verne stimulation
Description: Non-invasive and short electrical stimulation by placing the stimulating electrode at the cymba conchae of the left ear. The reference electrode is placed near the left cymba conchae. It provides a light tingling, massaging feeling in the ear.
Study NCT05057949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotinib
Description: Larotinib Capsules
Study NCT05057949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin Capsules
Study NCT05057949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole Capsules
Study NCT05157282 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TESS
Description: Small stimulation pulses will be given to the spine at C5-6 in a non invasive manner.
Study NCT05157282 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TESS
Description: Small stimulation pulses will be given to the spine at C5-6 in a non invasive manner.
Study NCT05157282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: The participant will be instructed to do repetitive motor movements with their arm or hand.
Study NCT05157282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor Task
Description: Participants will be asked to perform specific motor tasks or movements with their fingers, hands, and arms.
Study NCT05157282 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Motor Task
Description: Participants will be asked to perform specific motor tasks or movements with their fingers, hands, and arms.
Study NCT05157282 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham-TESS
Description: Small sham stimulation pulses will be given to the spine at C5-6 in a non invasive manner.
Study NCT05161039 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Serranator
Description: Serranator® PTA Serration Balloon Catheter manufactured by Cagent Vascular
Study NCT05161039 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: POBA
Description: Plain balloon angioplasty device
Study NCT05157282 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-TESS
Description: Small sham stimulation pulses will be given to the spine at C5-6 in a non invasive manner.
Study NCT05279937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose 50% Intravenous Solution
Description: 5mL of 50% Dextrose + 5mL of 1% Lidocaine (Prolotherapy).
Study NCT05279937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 1% Injectable Solution
Description: 10mL of 1% Lidocaine (Control)
Study NCT05456100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Helping
Description: Expressive helping involves a combination of emotional disclosure and peer support writing completed over four weeks.
Study NCT05456100 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expressive Writing
Description: Expressive writing involves emotional disclosure writing over four weeks.
Study NCT05456100 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Factual Writing
Description: Factual writing involves writing facts about cancer treatment and experiences over four weeks.
Study NCT05269849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus (1, 2, or 5 mg tablets) given for 3 months followed by a washout period of 3 months
Study NCT06559137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2% Injectable Solution
Description: Patients who are randomized to the peripheral nerve block group will receive a pre-operative perineural injection of 0.2% plain Ropivacaine regardless of weight.
Study NCT06649903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chiropractic
Description: high speed low amplitude neck manipulation
Study NCT06649903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Osteopathy
Description: the stomach and liver technique was applied
Study NCT04906005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gadopiclenol
Description: administration by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a saline flush of at least 5 mL at the same rate to ensure complete injection of the contrast agent.The gadopiclenol administration is performed by power injecto
Study NCT04906005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous (IV) bolus injection at 2 mL/s, followed by a saline flush of at least 5 mL to be in the same conditions as for gadopiclenol administration.The gadopiclenol administration is performed by power injector
Study NCT05073770 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titan Condom
Description: The test condoms have the following specifications throughout the study:~1. The plain 64mm condom (i.e., N64): Length 223 ±5mm, width 64±1mm, thickness (single wall) 0.070± 0.005mm, and beading thickness 1.25±0.05mm.~2. The plain 69mm condom (i.e., N69): Length 223 ±5mm, Width 69±1mm, Thickness (single wall) 0.070± 0.005mm, Beading thickness 1.25±0.05mm.
Study NCT05099601 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Silymarin
Description: The patients will use topical silymarin 0.7% cream on the face twice daily(home use).
Study NCT05099601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microneedling
Description: Patients will be subjected to microneedling sessions on one side of the face. Three consecutive sessions, 4 weeks apart (0, 4, 8 weeks), will be performed by dermapen. Sessions will be done by well trained physician.
Study NCT05677789 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Medical observation
Description: Likely suitable for home treatment
Study NCT05677789 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Supportive treatment (BSC)
Description: Consider hospital supervised treatment
Study NCT05677789 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intensive care management
Description: Manage in hospital as severe pneumonia
Study NCT05389800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper Extremity Aerobic Exercise
Description: Using a cycle-ergometer (Monark 881E)
Study NCT06391801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuroathletic training
Description: Specific Neuroathletic training exercises were performed to improve balance ability of post stroke patients
Study NCT06391801 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional movement therapy in outpatient rehabilitation
Description: Traditional movement therapy in outpatient rehabilitation
Study NCT04779931 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Convoy-Pal
Description: 12 week mobile self-management intervention with palliative care resources.
Study NCT04779931 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Convoy-Pal
Description: 12 week mobile self-management intervention with palliative care resources.
Study NCT06156124 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Psychological tests and psychosocial questionnaires
Description: Assessment of psychological functioning of adolescents (including occurrence of internalizing and externalizing problems, coping with adolescent crisis), family functioning (siblings relations, parental attitudes, parentification), functioning at school (school achievement, extracurricular activities), relations with peers (time spending with peers, number of friends, quality of relations). Further, the sociodemographic variables will be also measured.
Study NCT05366205 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement
Description: Enteral nutritional emulsion(TPF-T) will be given by oral intake,400ml per day, lasting for 7-10 days.
Study NCT05366205 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Nutrition consultation
Description: Nutritional treatment advice will be given
Study NCT05404984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry cupping with core stabilization exercises
Description: 12 patients will receive dry cupping technique for 10 minutes followed by 10 repetitions of each core stabilization exercise in different positions. All the patients will receive this treatment once a week for 6 weeks.
Study NCT05404984 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core stabilization exercises
Description: A total of 12 patients will perform 10 repetitions of each core stabilization exercise in different positions. All the patients will receive this treatment once a week for 6 weeks.
Study NCT05873140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: application LINE
Description: Online lifestyle modification education for weight loss
Study NCT05955859 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Samplings from patient's affected paranasal sinus
Description: Samplings from patient's affected paranasal sinus during endoscopic surgery.